Reddit Posts
Next Tuesday, Houston federal court judge hears SCLX vs the big bad Investment banks on ILLEGAL NAKED SHORTING. SHOW ME THE ILLEGAL PROFITS
SCLX stock collapse by shorts 50% drop <2 trading days
SCLX from $11 pre-market to $15. Shorters are desperate and failing
SCLX/SRNEQ Federal Judge subpoenas delivered to 25 brokers for disclosure of shorts by 4/14 COB
While the band of pumpers pump the same loser stocks that go nowhere (NVOS, TRKA, PXMD etc.), I call another big winner in BANL
SCLX a meme stock speculation or maybe SCLXW
SCLX ... lots of shorts and naked shorts ... SCLX and courts file to hold brokerages accountable
SCLX Might be the Short Squeeze Meme Traders Have Been Waiting For
SCLX unaccounted for restricted shares non marginable may be used to short SCLX ?
SCLX SHORT SQUEEZE? Anyone have information
SCLX looks legit - brokers legally forced to report due to SRNEQ bankruptcy
How About The Massive Move From $SCLX GUYS 🔥 We Seen This One Coming A Mile Away ! Holy Smokes , Right After $IFRX 🔥
SCLX just started today. Judge order initiated. You still have time to jump on the bandwagon.
SCLX is a major short squeeze in beginning....
SRNE / SCLX is this a squeeze in the making?
$SCLX - Company trying to engineer mother of short squeezes here
Mentions
$NMHI $SCLX $FFAI $Burke's Products $WGRX These companies are related to $DVLT. Anyone knows their friends or family members who work for these companies? Do these companies really exist?
Yes, Scilex Holding Co is a real company. It’s a biopharmaceutical firm specializing in acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain. Key details include: • Headquarters: 960 San Antonio Road, Palo Alto, CA 94303, USA. • Founded/Listed: Publicly traded on Nasdaq under the ticker SCLX since November 11, 2022. • Products: Their commercial product is ZTlido (lidocaine topical system) for postherpetic neuralgia. They’re also advancing candidates like SEMDEXA (SP-102), a triple-strength ZTlido (SP-103), and SP-104 (low-dose naltrexone). • Employees: Approximately 31. • Website: scilexholding.com. This information is based on current financial market data as of November 2025.
I heard it was way up on moneyvest daily update. like $5 from ATH. My week is looking great, Hit ATH this morning. I made 4k off DVLT and SCLX... plus all my solid shit is blowing up. https://preview.redd.it/eegy2e8n0yxf1.png?width=935&format=png&auto=webp&s=af379d827fa491d2405654f6da336b0c44f87d57
They'll only issue the missing shares to transfer to SCLX, and these shares have a lockup period, meaning a limitation, according to the agreement!!! Moreover, selling them to SCLX in the coming years is extremely illogical and unreasonable, and that's not why they invested 150 million. This isn't just dilution and a direct release onto the market; it's SCLX's right to a seat on the board of directors, based on DVLT's decisions. This is an investment in DVLT's future.
DVLT just got $150M bitcoin investment from SCLX. Has two leading tech plays. STRONG!
I was a SRNE and SCLX shareholder. The story is long and complicated. SCLX owns 87% of SMNR, which just started trading on the OTC this week (though for some reason only a few tens of shares have traded) after closing a business combination with Denali (a spac deal). If I recall correctly, SCLX got a $200M bitcoin investment very recenty from an investor—who got $200M of SMNR stock in exchange. So apparently SCLX took $150M of it and put it into DVLT. Seems very bullish and DVLT is poised to take off. Let’s see how high and fast.
Anyone saying it is a dilution here knows nothing about strategic investment with Board of Directors appointment involved. LMFAO the details will be further disclosed but there MUST a lock up period at least a year for the shares issued to SCLX.
[Semnur Pharmaceuticals, Inc Announces Signing of a Securities Purchase Agreement with an Institutional Investor for the Purchase of $100 Million of shares of Semnur Common Stock in Exchange for $100 Million in Bitcoin](https://www.globenewswire.com/news-release/2025/09/23/3154932/0/en/Semnur-Pharmaceuticals-Inc-Semnur-a-Majority-Owned-Subsidiary-of-Scilex-Holding-Company-Nasdaq-SCLX-Scilex-Announces-Signing-of-a-Securities-Purchase-Agreement-with-an-Institutiona.html) \- OTC: SMNR SMNRW SMNR wasting zero time jumping into the crypto pool, business combination just closed yesterday. SMNR and SMNRW each have only traded 100 shares today, SMNR up 65% and SMNRW up 650%. Reposting this from yesterday: [Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination](https://www.globenewswire.com/news-release/2025/09/22/3154269/0/en/Semnur-Pharmaceuticals-Inc-Semnur-a-Majority-Owned-Subsidiary-of-Scilex-Holding-Company-Nasdaq-SCLX-Scilex-and-Denali-Capital-Acquisition-Corp-Announce-the-Closing-of-Their-Previou.html) \- OTC: DNQAF DNQWF -> OTC: SMNR SMNRW on September 23, 2025 Looks like NASDAQ did **NOT** approve SMNR for listing, so this will continue to trade on the OTC market. [Last trade for DNQAF](https://www.otcmarkets.com/stock/DNQAF/overview#:~:text=MORE-,TRADE%20DATA,-DATE) shows as 100 shares ( day's total ) on August 22. There were [43,739 shares subject to possible redemption as of June 30, 2025](https://www.sec.gov/Archives/edgar/data/1913577/000121390025077047/ea0251993-10q_denali.htm#:~:text=43%2C739%20and%20751%2C837%20shares%20subject%20to%20possible%20redemption%20as%20of%20June%2030%2C%202025), Denali did not provide redemption information for the business combination vote, so total public float unknown but may be less than 40k.
[Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination](https://www.globenewswire.com/news-release/2025/09/22/3154269/0/en/Semnur-Pharmaceuticals-Inc-Semnur-a-Majority-Owned-Subsidiary-of-Scilex-Holding-Company-Nasdaq-SCLX-Scilex-and-Denali-Capital-Acquisition-Corp-Announce-the-Closing-of-Their-Previou.html) \- OTC: DNQAF DNQWF -> OTC: SMNR SMNRW on September 23, 2025 Looks like NASDAQ did **NOT** approve SMNR for listing, so this will continue to trade on the OTC market. [Last trade for DNQAF](https://www.otcmarkets.com/stock/DNQAF/overview#:~:text=MORE-,TRADE%20DATA,-DATE) shows as 100 shares ( day's total ) on August 22. There were [43,739 shares subject to possible redemption as of June 30, 2025](https://www.sec.gov/Archives/edgar/data/1913577/000121390025077047/ea0251993-10q_denali.htm#:~:text=43%2C739%20and%20751%2C837%20shares%20subject%20to%20possible%20redemption%20as%20of%20June%2030%2C%202025), Denali did not provide redemption information for the business combination vote, so total public float unknown but may be less than 40k.
Buy Scilex SCLX now! Massive short squeeze happening now!
Thank you for posting these every week, I did made some nice amount of profit on SCLX, AVBP and IMRX. Love you man! Keep doing what you are doing...
Been in this one since the IPO spun out of SRNE now on life support waiting for a heart donor but still has a ton of potential in that GMAB pipeline. Scilex was spun out to focus on non-opioid pain management phase 3 CT's with outstanding trial results and no adverse side effects to date. Non-Opiod as in Opiod Epidemic as in Physician Liability for prescribing narcotics with opioids like Oxy... if the non-opiod pain meds break through that decades long barrier and provide real pain relief then this is a global game changer. Extracted from the root of a plant grown in N.Africa, this known pain blocker has been tested by dozens of biotechs to achieve approval and commercial viability but all of them failed to get past phase 1 clinical trials. Scilex is in the second half of phase 3 clinical trials having met or exceeded the goals set by FDA for the first segment of P3 in 2023 before the parent company Sorrento Theraputics filed for Chapter 11 putting everyone into a holding pattern for 20 months. This week the merger between Scilex and Denali capital to form a new biotech focused on final NDA approvals SP-102 and SP-103 non-opiod pain drug candidates was confirmed by Denali BoD vote. The new entity will be called Semnur Pharmaceutical and Scilex shareholders will receive new shares of Semnur Pharma which will surely skyrocket after years of naked short selling. Warrants are up as a hedge for short sellers but can't be exercised until the stock hits $402.5 after 35:1 reverse split formerly $11 price target for the warrants to become valid. Today SCLX trades at $20 which is below a dollar pre reverse split and had reached a price of $10.50 before SRNE filed chapter 11. $10.50 x 35 is where we expect to be very soon @ $365 share. I'd say the $20 price today is a steal especially when we consider the float and the borrow rate for short sellers has reached a danger level of 35% putting Scilex/Semnur at the top of the list for potential SQ. Do your own DD. Diamond hands.
SCLX squeeze may also impact SRNE. Important to remember how the shorting of SRNE links to the original SCLX divs. Those open naked short SRNE positions as of the original SOR date for the SCLX div owed the SCLX div to those who bought SRNE. So, a SCLX squeeze could easily drive up SRNE.
Limited SCLX float (roughly 6.9M shares post-RS) combined with to be announced SMNR dividend to SCLX shareholders will make it expensive for shorts - especially naked shorts, to exit.
[Semnur Pharmaceuticals, Inc, a Majority-Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business Combination](https://www.globenewswire.com/news-release/2025/09/04/3144605/0/en/Semnur-Pharmaceuticals-Inc-Semnur-a-Majority-Owned-Subsidiary-of-Scilex-Holding-Company-Nasdaq-SCLX-Scilex-and-Denali-Capital-Acquisition-Corp-Announce-Approval-from-Denali-s-Share.html) \- OTC: DNQAF DNQWF "upon consummation of the Business Combination, which is expected to close in September 2025, subject to satisfaction of customary closing conditions" Looks like [43,739 public shares were remaining before the business combination meeting](https://www.sec.gov/Archives/edgar/data/1913577/000121390025077047/ea0251993-10q_denali.htm#:~:text=43%2C739%20and%20751%2C837%20shares%20subject%20to%20possible%20redemption%20as%20of%20June%2030%2C%202025), no redemption info for that yet.
Onboard for NRXP and THTX and I’m watch SCLX
\#SCLX is facing the same fate, check it out! #SQUEEZEHAPPENINGNOW
Listen, I don't mean to break any rules or anything, but I really am genuinely curious about SCLX. the did a 1-35 split and are currently running up a LOT. The current analyst estimates are it will hit 250 average in the next 12 months, almost 2500% up from current price.. ([DATA](https://www.marketbeat.com/stocks/NASDAQ/SCLX/forecast/)). Is this a weird mix-up or something? It seems like every website out there is predicting nearly the same thing.. I don't own anything in this. I was just doing research on up and coming companies, and this came up. They just had several breakthrough drugs so that's why it is moving, but that expectation is BONKERS...
$SCLX - [https://www.reddit.com/r/BANDOFBROTHERSOFSRNE/comments/1mk03ww/naked\_shorting\_proved/](https://www.reddit.com/r/BANDOFBROTHERSOFSRNE/comments/1mk03ww/naked_shorting_proved/)
SCLX been on a tear lately
SCLX short interest is almost 10%. Is the juice worth the squeeze?
SCLX has been doing really well for me
I already have my nuts drenched in that crap down 60% on my SCLX and 99.9% on my SRNE investment.
$SCLX buy now, earning announcement coming up on 11/14. Currently @ $.86 per share
SCLX! Non opioid pain medications.
Absolutely: Scilex Holding Company (SCLX) is currently experiencing positive sentiment, with technical indicators suggesting a bullish outlook. The stock's RSI values indicate it's nearing overbought territory, but the MACD histogram shows strong upward momentum, supporting potential gains. The 10-day SMA at $0.953 and the current price of $1.02 suggest a breakout above recent averages, aligning with broader market optimism driven by anticipated rate cuts. However, the lack of trading volume today raises caution about liquidity and potential volatility. Given the positive sentiment and technical setup, consider a LONG position with an entry around $1.02. Set the first price target at $1.10 and a second at $1.15, with a stop loss at $0.95 to manage downside risk. Confidence in reaching the first target is moderate due to strong momentum, while the second target carries lower confidence given potential market volatility.
Absolutely: LCID: Lucid Group, Inc. (LCID) is currently trading at $2.275, with a mixed sentiment but a slight positive tilt due to the recent $1 billion investment by the Saudi sovereign wealth fund and a 14% sales growth from September to October. The stock is heavily shorted, with 25% of the float shorted, indicating potential for a short squeeze, especially with the upcoming earnings report on November 7th. Technical indicators show a bearish trend, with the RSI below 30, suggesting the stock is oversold, while the MACD histogram is negative, indicating downward momentum. The broader market shows cautious optimism, which could support LCID if tech sector strength continues. For today's session, consider a LONG position with an entry price around $2.25, targeting $2.40 as the first target and $2.55 as the second, with a stop loss at $2.15. Confidence in reaching the first target is moderate due to potential short squeeze dynamics, while the second target is less certain given the current bearish technicals. Keep an eye on broader market movements and any news related to Lucid's production expansion or upcoming earnings for further insights. SCLX: Scilex Holding Company (SCLX) is currently experiencing positive sentiment, with technical indicators suggesting a bullish outlook. The stock's RSI values indicate it's nearing overbought territory, but the MACD histogram shows strong upward momentum, supporting potential gains. The 10-day SMA at $0.953 and the current price of $1.02 suggest a breakout above recent averages, aligning with broader market optimism driven by anticipated rate cuts. However, the lack of trading volume today raises caution about liquidity and potential volatility. Given the positive sentiment and technical setup, consider a LONG position with an entry around $1.02. Set the first price target at $1.10 and a second at $1.15, with a stop loss at $0.95 to manage downside risk. Confidence in reaching the first target is moderate due to strong momentum, while the second target carries lower confidence given potential market volatility. MAXN: Maxeon Solar Technologies (MAXN) is experiencing heightened volatility, driven by mixed sentiment and potential short squeeze dynamics. The stock's RSI values indicate overbought conditions, suggesting caution for new long positions. Recent price action shows a strong upward trend, with the current price at $9.69, significantly above key moving averages, indicating bullish momentum. However, skepticism about the company's fundamentals and negative margins could limit upside potential. Given the broader market's cautious optimism and MAXN's speculative nature, a short-term long position could be considered with an entry around $9.50. Target the first price at $10.50 and a second at $11.00, with a stop loss at $8.80 to manage downside risk. Confidence in reaching the first target is moderate due to potential short squeeze effects, while the second target carries lower confidence given fundamental concerns.
LCID, SCLX, MAXN please and thank you!!
It’s way at the bottom under the subscribe button. I like SCLX too, but it’s worth noting the bias of the website/article. I would take this into consideration with anything this website puts out. Anyway,I copied the text below. “Huge Alerts has been compensated by CDMG Inc for the total sum of $350,000.00 This agreement is for the marketing of Scilex Holdings (NASDAQ:SCLX) which services include the issuance of this release and other opinions that we release concerning of Scilex Holdings (NASDAQ:SCLX). Huge Alerts has not investigated the background of CDMG Inc the hiring party, or Scilex Holdings (NASDAQ:SCLX) Anyone viewing this newsletter should assume CDMG Inc or affiliates of CDMG inc own shares of Scilex Holdings (NASDAQ:SCLX) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Huge Alerts has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding Scilex Holdings (NASDAQ:SCLX)”
November on through the first quarter 2025 seems to be extremely bullish from my research. Stock Price Target SCLX High $14.00 Median $10.00 Low $5.50 Average $9.88 Current Price $1.00
Great idea, though I can't seem to find $SCLX
SCLX: https://scilexholding.gcs-web.com/node/9436/html https://scilexholding.gcs-web.com/news-releases/news-release-details/scilex-pharmaceuticals-inc-wholly-owned-subsidiary-scilex
SCLX: https://scilexholding.gcs-web.com/news-releases/news-release-details/scilex-pharmaceuticals-inc-wholly-owned-subsidiary-scilex https://scilexholding.gcs-web.com/node/9436/html HINT: 🚀🚀🚀
Scilex Holding Company (SCLX) is currently trading at $1.03, showing a bullish momentum with recent news addressing manipulative short selling and a strategic dividend announcement that could enhance shareholder value. The technical indicators are supportive, with the 10-day SMA at $0.94 and the 8-day EMA at $0.94, both above the current price, suggesting potential upward movement. The RSI levels indicate moderate strength, not yet overbought, while the MACD histogram shows positive divergence, hinting at continued bullish momentum. Given the broader market’s resilience and SCLX’s proactive measures, an entry around $1.02 is advisable. Set the first price target at $1.10 with a confidence level of 70%, considering the positive sentiment and technical setup, and a second target at $1.15 with a 60% confidence level, factoring in potential volatility from broader market influences. A stop loss at $0.98 is prudent to manage downside risk. Overall, SCLX presents a compelling opportunity for day traders looking to capitalize on its current momentum and strategic initiatives.
SCLX: Non opioid pain relief. Opioids are a big problem and this mess is starting to get cleaned up. The solution is to have options and I believe Scilex will provide those options for chronic pain.
Loaded up on SCLX and TNXP for the short squeeze play. SCLX has some potential for a short squeeze, with growing short interest and a relatively small float, making it an interesting speculative play. I'm 80/20 on it, TNXP isn't as high potential for squeeezeee.
Parent company is sorrento and the reason the dividend shares are locked up is because they burned their shareholders and then “gifted” them SCLX shares, have been pushing the dividend back consistently too when each lockup approaches, this company had serious potential but the share price has been decimated, potentially some upside but I’d be cautious
Of course: Scilex Holding Company (SCLX) is showing signs of bullish momentum, with the current price at $0.9601 and a recent uptick in trading volume, although still below its 65-day average. The technical indicators suggest a positive outlook: the 8-day EMA ($0.9202) is above the 20-day EMA ($0.9150), and the MACD histogram is positive, indicating potential upward momentum. The RSI is nearing overbought territory at 69.5, suggesting caution but not yet signaling a reversal. Given the broader market’s cautious optimism, SCLX could benefit from sector rotation into healthcare. For today’s session, consider entering around $0.95, with a first target at $1.00 and a second target at $1.05, setting a stop loss at $0.92 to manage risk. Confidence in reaching the first target is moderate due to the positive technical setup, while the second target carries lower confidence given potential resistance and broader market volatility.
Can you tell us a little on SCLX
SCLX is looking quite interesting…
You missed the punch line, "SEMDEXA", non-opioid pain med. Has met all of the end points and is getting ready to finish the testing regimen. This is the crown jewel in the SCLX stable. How much is the first major non-opioid pain med for sciatica that appears to be superior to the current opioid meds.
You also get a 10% divy in stock of SEMNUR shares a spac merger with Denali acquisition for every SCLX share you own in early 2025.
might not mean shit but on Trading212 for a brief moment this morning a little yellow notice appeard stating that $SCLX was not tradable, it was only on screen for a minute or two then vanished.
Pfff...SCLX has 11M shares in the hands of the shorts .this is not good at all.
**$SCLX** agree... this stock has huge potential
Scilex Holding Company ( SCLX SCLXW ) has a market cap of $234 million, and the subsidiary is valued at $2.5 billion?
Silex $SCLX is once again in oversold territory and might be turning back up? If it closes above 1.30 that would be the sign it's time to buy. If you played it right over the past year, you would have made 100% four times!
SCLX: Possible dividend in play, insider buying, and now this- https://finance.yahoo.com/news/scilex-holding-company-announces-collaboration-130000600.html
Silex $SCLX just signed a deal with ACEA Therapeutics to distribute their non-narcotic chronic pain medications in China, opening up a huge potential market. This stock currently trades just under 2.00 but not for long
Silex $SCLX is trading close to yesterday's close under a lot of downward manipulation. Right now may be your last chance to buy this great company under 2.00. Just read the most recent PR that sent this stock to 2.73 after hours. It will be back there again soon
>for up to 2 billion (lol). "subject to adjustment based on third-party fairness opinion" SCLX has a market cap of $345 million. Wonder what third party would think one of SCLX's subsidiaries is worth $2 billion?
[DECA with a quick turnaround, LOI with SCLX (who also SPACed) subsidiary for up to 2 billion (lol).](https://www.globenewswire.com/news-release/2024/07/02/2907841/0/en/Semnur-Pharmaceuticals-Inc-a-Wholly-Owned-Subsidiary-of-Scilex-Holding-Company-and-Denali-Capital-Acquisition-Corp-Nasdaq-DECA-Enter-into-a-Letter-of-Intent-for-a-Proposed-Business.html)
Silex $SCLX continues to march forward. If you didn't add some shares when I was talking about it at .80 it's not too late. It's currently 2.03 and expected to go over 3.00 by the end of July. This Friday they will ring the NASDAQ bell. Won't be a penny stock for long IMO
Can someone buy my instant profit SCLX $2 6/21 put? I have no capital to exercise. $0.20
Can someone buy my instant profit SCLX $2 6/21 put? I have no capital to exercise. $0.20
Correction on the way for SCLX
SCLX Naked short squeeze started todayemote:free\_emotes\_pack:upvote
All of y'all who downvoted me on SCLX we hit $2. ( Posted about the company when it was at $0.90) Eat a frank 
Ive been downvoted to oblivion for posting about SCLX since it was $0.90 ..... We hit $1.80 today 
Another 11% day on SCLX Gave you guys a mini DD yesterday.
(3rd Reddit account so not enough Karma to make a post so Ill just leave it here ) Scilex Holding Company released/launched its 3rd commercial product, "GLOPERBA" on Monday (June 10th, 2024) which is looking fairly successful. Some background on SCLX if you've never heard of them. Scilex Holding Company develops and commercialize non opioid pain medications for minor to severe pain. Right now (and past couple years) we have seen a consistent increase in Opioid addiction and overdoses. It will only get worse from the looks of it. They have already shipped their new product to many National and Independent Drugstores/Pharmacies. Below I will leave info on what the product/medicine is and what it treats. ""GLOPERBA will be the first oral liquid medicine for prophylaxis of gout flares available beginning this week with a WAC Price of $595/bottle."" and theyre ""Gout is a painful arthritic disorder affecting an estimated 9.2 million people in the United States^(1). As gout cases increase every year, treatment requirements increase. The gout treatment market is projected to be $2.0 billion in the U.S. by 2028 "" (I also left a link to a article talking about the opioid crisis a little bit. "Fourth wave") ""The United States is knee-deep in what some experts call the opioid epidemic’s “fourth wave,”"
SCLX is seeing some nice movement today. Wonder if it will stay that way until EOW.
Tomorrow, SCLX: https://scilexholding.gcs-web.com/news-releases/news-release-details/scilex-holding-company-announces-us-fda-has-approved-snda
SCLX. A producer of revolutionary non-opioid pain relief medicine. Stock went from 16 to 1.10 because of the naked short selling.
We need these companies on the SHO list to follow this lead https://finance.yahoo.com/news/scilex-holding-company-sends-letter-130000733.html PALO ALTO, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focu...
SCLX to $3-$4 by end of June 
Not too late to pick up Scilex $SCLX. I've been posting here since it was around .80, now 1.19. But it's got a long way to run. Non-narcotic pain meds very popular with pain specialists and patented patch technology
SCLX is looking like a great buy right now
SCLX is going to have some nice movement come Tuesday. 
Just announced "Scilex ($SCLX) will be added to the MSCI Global Micro Cap Index as of the close of market on Friday, May 31, 2024."
(SCLX) Thoughts on this letter? [https://ml.globenewswire.com/Resource/Download/0a05a41f-47b1-4b67-8aac-38492551a6ce](https://ml.globenewswire.com/Resource/Download/0a05a41f-47b1-4b67-8aac-38492551a6ce)
Article today in Simply Wall St says insiders are buying and holding Silex $SCLX. 1 YR est is now at 7.00. Currently trading at 1.08
Scilex #SCLX is moving up today. I've been telling folks for awhile this has been oversold and slowly taking off. Now filings indicate several company officers have bought hundreds of thousands of shares. Not to late to get in at 1.20. This is headed back over 2.00